Video Library

See other stories

Instructional Videos

Cetrotide® (cetrorelix acetate for injection) - 0.25mg | Getting Ready
Gonal-f® Multi-Dose - Getting Ready
Gonal-f® RFF 75 IU - Getting Ready
Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) - Getting Ready
Cetrotide® (cetrorelix acetate for injection) - 0.25mg | Step 1: Mix
Cetrotide® (cetrorelix acetate for injection) - 0.25mg | Step 2: Preparing Your Injection
Cetrotide® (cetrorelix acetate for injection) - 0.25mg | Step 3: Inject
Cetrotide® (cetrorelix acetate for injection) - 0.25mg | Step 4: Disposal
Gonal-f® Multi-Dose - Disposal
Gonal-f® Multi-Dose - Step 1: Mix
Gonal-f® Multi-Dose - Step 2: Draw Up
Gonal-f® Multi-Dose - Step 3: Inject
Gonal-f® RFF 75 IU - Disposal
Gonal-f® RFF 75 IU - Step 1: Mix
Gonal-f® RFF 75 IU - Step 2: Draw up
Gonal-f® RFF 75 IU - Step 3: Inject
Gonal-f® RFF Redi-ject™ - Step 1: Preparing the Pen
Gonal-f® RFF Redi-ject™ - Step 2: Attaching the needle to the Pen
Gonal-f® RFF Redi-ject™ - Step 3: Removing large air bubbles from the Pen
Gonal-f® RFF Redi-ject™ - Step 4: Selecting the correct dose of Gonal-f® RFF Redi-ject™
Gonal-f® RFF Redi-ject™ - Step 5: Selecting the injection site and injecting your dose of Gonal-f® RFF Redi-ject™
Gonal-f® RFF Redi-ject™ - Step 6: What to do when your injection is completed
Gonal-f® RFF Redi-ject™ - Step 7: Disposal of your needles and Pens
Gonal-f® RFF Redi-ject™ - Step 8: Recording the Gonal-f® RFF Redi-ject™ injection in your treatment library
Gonal-f® RFF Redi-ject™ - Step 9: Storing your pen
Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) - Disposal
Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) - Step 1: Preparing Your Injection
Ovidrel® PreFilled Syringe (choriogonadotropin alfa injection) - Step 2: Inject

Scientific Animation

Natural Monthly Cycle: Day 01
Natural Monthly Cycle: Day 02
Natural Monthly Cycle: Day 03
Natural Monthly Cycle: Day 04
Natural Monthly Cycle: Day 05
Natural Monthly Cycle: Day 06
Natural Monthly Cycle: Day 07
Natural Monthly Cycle: Day 08
Natural Monthly Cycle: Day 09
Natural Monthly Cycle: Day 10
Natural Monthly Cycle: Day 11
Natural Monthly Cycle: Day 12
Natural Monthly Cycle: Day 13
Natural Monthly Cycle: Day 14
Natural Monthly Cycle: Day 15
Natural Monthly Cycle: Day 16
Natural Monthly Cycle: Day 17
Natural Monthly Cycle: Day 18
Natural Monthly Cycle: Day 19
Natural Monthly Cycle: Day 20
Natural Monthly Cycle: Day 21
Natural Monthly Cycle: Day 22
Natural Monthly Cycle: Day 23
Natural Monthly Cycle: Day 24
Natural Monthly Cycle: Day 25
Natural Monthly Cycle: Day 26
Natural Monthly Cycle: Day 27
Natural Monthly Cycle: Day 28
Ovulation Induction Treatment
The Fine Art of ART: Day 01
The Fine Art of ART: Day 02
The Fine Art of ART: Day 03
The Fine Art of ART: Day 04
The Fine Art of ART: Day 05
The Fine Art of ART: Day 06
The Fine Art of ART: Day 07
The Fine Art of ART: Day 08
The Fine Art of ART: Day 09
The Fine Art of ART: Day 10
The Fine Art of ART: Day 11
The Fine Art of ART: Day 12
The Fine Art of ART: Day 13
The Fine Art of ART: Day 14
The Fine Art of ART: Day 15
The Fine Art of ART: Day 16
The Fine Art of ART: Day 17
The Fine Art of ART: Day 18
The Fine Art of ART: Day 19
The Fine Art of ART: Day 20
The Fine Art of ART: Day 21
The Fine Art of ART: Day 22
The Fine Art of ART: Day 23
The Fine Art of ART: Day 24
The Fine Art of ART: Day 25
The Fine Art of ART: Day 26
The Fine Art of ART: Day 27
The Fine Art of ART: Day 28

Fundamentals of Fertility

Normal Reproductive Physiology

IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF Gonal-f RFF® Redi-jectTM (follitropin alfa injection)

Indications and Usage: 

  • Induction of ovulation (OI) and pregnancy in oligo-anovulatory women in whom the cause of infertility is functional and not due to primary ovarian failure
  • Development of multiple follicles in ovulatory women as part of an Assisted Reproductive Technology (ART) cycle.
    • Prior to treatment, complete an evaluation of female and male partners to determine infertility diagnosis. Primary ovarian failure and potential pregnancy should be excluded.

Contraindications:

  • hypersensitivity to rhFSH preparations or excipients
  • high levels of FSH indicating primary gonadal failure
  • pregnancy (Pregnancy Category X)
  • uncontrolled non-gonadal endocrinopathies (thyroid, adrenal, pituitary disorders)
  • sex hormone dependent tumors of the reproductive tract and accessory organs
  • tumors of pituitary gland or hypothalamus
  • abnormal uterine bleeding
  • ovarian cyst or enlargement of undetermined origin, not due to polycystic ovary syndrome.

Warnings and Precautions:

  • For use by physicians specializing in fertility treatment or reproductive health and only when appropriate monitoring facilities are available.
  • Gonal-f® RFF Redi-ject™ is a potent gonadotropin.  The lowest effective dose should be used given risk of abnormal ovarian enlargement and Ovarian Hyperstimulation Syndrome (OHSS).  Ultrasound monitoring of ovarian response and/or measurement of estradiol levels are important to minimize risks.  If symptoms of OHSS (severe pelvic or abdominal pain and distension, nausea, vomiting, diarrhea, severe ovarian enlargement, weight gain, dyspnea, oliguria) develop, all gondotropin treatment should be stopped, hCG should be withheld, and intercourse should be prohibited.  OHSS can be severe and requires hospitalization and treatment of fluid and electrolyte imbalances.  OHSS may occur with or without pregnancy.  Women should be assessed for the development of OHSS for at least two weeks after hCG administration.
  • Serious systemic hypersensitivity reactions, including anaphylaxis, have been reported in the postmarketing experience.  Symptoms have included dyspnea, facial edema, pruritis, and urticaria.  If an anaphylactic or other serious allergic reaction occurs, initiate appropriate therapy including supportive measures if cardiovascular instability and/or respiratory compromise occur, and discontinue further use.
  • Thromboembolic events both in association with, and separate from OHSS have been reported in women treated with gonadotropins.  Women with generally recognized risk factors for thrombosis, such as personal or family history, severe obesity, or thrombophilia, may have an increased risk of venous or arterial thromboembolic events, during or following treatment with gonadotropins.  Sequelae of such reactions have included venous thrombophlebitis, pulmonary embolism, pulmonary infarction, cerebral vascular occlusion (stroke), and arterial occlusion resulting in loss of limb and rarely in myocardial infarctions.  In rare cases, pulmonary complications and/or thromboembolic reactions have resulted in death.  In women with recognized risk factors, the benefits of OI and ART need to be weighed against the risks.
  • Serious pulmonary conditions (e.g., atelectasis, acute respiratory distress syndrome and exacerbation of asthma) have been reported in women treated with gonadotropins.
  • Ovarian torsion has been reported after treatment with gonadotropins.  This may be related to OHSS, pregnancy, previous abdominal surgery, past history of ovarian torsion, previous or current ovarian cyst and polycystic ovaries.  Damage to the ovary due to reduced blood supply can be limited by early diagnosis and immediate detorsion.
  • The couple should be advised of the potential risk of multi-fetal gestation and birth before beginning therapy.  During clinical trials, multiple births occurred in 20% of live births in women receiving therapy for ovulation induction and 35.1 % of live births in women undergoing ART.
  • The incidence of congenital malformations after some ART [specifically in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI)] may be slightly higher than after spontaneous conception. This slightly higher incidence is thought to be related to differences in parental characteristics (e.g., maternal age, maternal and paternal genetic background, sperm characteristics) and to the higher incidence of multi-fetal gestations after IVF or ICSI.
  • Since women undergoing ART often have tubal abnormalities, the incidence of ectopic pregnancy may be increased
  • The incidence of spontaneous abortion may be increased.  However, causality has not been established.  This may be a factor of the underlying infertility.
  • Both benign and malignant ovarian neoplasms have been infrequently reported; causality has not been established.
  • Both ultrasound and serum estradiol measurement should be used to monitor follicular growth and maturation, timing of the ovulatory trigger, detecting ovarian enlargement, and minimizing the risk of the OHSS and multiple gestation.

Adverse Reactions:

The most common adverse reactions (≥5%) in OI include: headache, abdominal pain, and ovarian hyperstimulation.  The most common adverse reactions (≥5%) in ART include: abdominal pain, nausea, abdominal enlargement, headache, and injection site reactions (pain, bruising).

Patient Counseling:

In addition to advising patients about the proper use of treatment, the duration and necessity of monitoring, handling of missed doses, OHSS, and multi-fetal gestation and birth, patients should be advised to review the Patient Information Leaflet which contains risk information, follow the Instructions for Use for the Gonal-f® RFF Redi-ject™, not share the device or reuse needles, and to ask their HCP about questions.

HCP should refer to the full Prescribing Information for full disclosure.

*revised formulation female


IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF GONAL-F® (follitropin alfa for injection):

Indication: 

For women, Gonal-f® (follitropin alfa for injection) and Gonal-f® RFF* (follitropin alfa injection) are indicated for 1) the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure and 2) for the development of multiple follicles in the ovulatory patient participating in an ART program. 

Gonal-f® is also indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.

Important Risk Information:  

These products should only be prescribed by physicians specializing in fertility or reproductive health.  Use of Gonal-f® or Gonal-f® RFF by women can result in multiple births.  Gonal-f® and Gonal-f® RFF  are potent gonadotropins capable of causing mild to severe adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary complications.  Gonal-f® and Gonal-f® RFF are contraindicated in women and men who exhibit prior hypersensitivity to recombinant FSH preparations or one of their excipients, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, sex hormone dependent tumors of the reproductive tract and accessory organs, and an organic intracranial lesion such as a pituitary tumor.  Additionally, Gonal-f® and Gonal-f® RFF  should not be given to women with abnormal bleeding,  presence or enlargement of an ovarian cyst of undetermined origin, or who are pregnant or nursing.  The most common side effects reported in women using Gonal-f® and Gonal-f® RFF include headache, abdominal pain, enlarged abdomen, ovarian cysts, nausea, and upper respiratory infections.  Men using Gonal-f® have commonly reported acne, breast pain and growth, fatigue.  Injection site reactions have been reported.

*revised formulation female


IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF OVIDREL® PREFILLED SYRINGE (choriogonadotropin alfa injection):

Ovidrel® PreFilled Syringe (choriogonadotropin alfa for injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an Assisted Reproductive Technology (ART) program such as in vitro fertilization (IVF) and embryo transfer.  Ovidrel® PreFilled Syringe is also indicated for the induction of ovulation (OI) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure.  Ovidrel®  PreFilled Syringe should only be used by physicians who are thoroughly familiar with infertility problems and their management.  

Ovidrel® PreFilled Syringe is a potent gonadotropic substance capable of causing Ovarian Hyperstimulation Syndrome (OHSS) in women with or without blood vessel or lung problems. Ovidrel®PreFilled Syringe is contraindicated in women who exhibit prior sensitivity to hCG preparations or their ingredients, primary ovarian failure, uncontrolled thyroid or adrenal dysfunction and pregnancy. Women who are nursing should also not use Ovidrel® PreFilled Syringe The most common side effects in women using Ovidrel® PreFilled Syringe include abdominal pain, injection site reactions, nausea and vomiting.  Reports of multiple births have been associated with Ovidrel® PreFilled Syringe treatment.  


IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF CETROTIDE® (cetrorelix acetate for injection):

Cetrotide® (cetrorelix acetate for injection) is indicated for the inhibition of premature LH surges in women undergoing controlled ovarian stimulation. Cetrotide® should be prescribed by physicians who are experienced in fertility treatment.

Cetrotide® is contraindicated in women who exhibit hypersensitivity to cetrorelix acetate, mannitol or medicines similar to Cetrotide®, who exhibit prior hypersensitivity to GnRH or any other GnRH analogs, or who are pregnant, are  breast-feeding or have severe kidney disease. Ovarian Hyperstimulation Syndrome (OHSS), with or without blood vessel or lung problems , can occur with the use of fertility drugs. Mild and short lasting injection reactions like reddening, itching and swelling at the injection sites may occur. Nausea and headache have also been reported.

© 2014 EMD Serono, Inc. and its affiliates.

This site contains medical information that is intended for residents of the United States only and is not meant to substitute for the advice provided by a medical professional. Always consult a physician if you have health concerns. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF GONAL-F® (follitropin alfa for injection):

IMPORTANT INFORMATION ABOUT THE PROPER USE AND RISKS OF GONAL-F® (follitropin alfa for injection):

Indication: 

For women, Gonal-f® (follitropin alfa for injection), Gonal-f® RFF (follitropin alfa injection) and Gonal-f® RFF Pen (follitropin alfa injection) are indicated for 1) the induction of ovulation and pregnancy in the anovulatory infertile patient in whom the cause of infertility is functional and not due to primary ovarian failure and 2) for the development of multiple follicles in the ovulatory patient participating in an ART program. 

Gonal-f® is also indicated for the induction of spermatogenesis in men with primary and secondary hypogonadotropic hypogonadism in whom the cause of infertility is not due to primary testicular failure.

Important Safety Information:  

These products should only be prescribed by physicians specializing in fertility or reproductive health.  Use of Gonal-f® or Gonal-f® RFF by women can result in multiple births.  Gonal-f® and Gonal-f® RFF  are potent gonadotropins capable of causing mild to severe adverse reactions, including Ovarian Hyperstimulation Syndrome (OHSS) in women with or without pulmonary complications.  Gonal-f® and Gonal-f® RFF are contraindicated in women and men who exhibit prior hypersensitivity to recombinant FSH preparations or one of their excipients, high levels of FSH indicating primary gonadal failure, uncontrolled thyroid or adrenal dysfunction, sex hormone dependent tumors of the reproductive tract and accessory organs, and an organic intracranial lesion such as a pituitary tumor.  Additionally, Gonal-f® and Gonal-f® RFF  should not be given to women with abnormal bleeding,  presence or enlargement of an ovarian cyst of undetermined origin, or who are pregnant or nursing.  The most common side effects reported in women using Gonal-f® and Gonal-f® RFF include headache, abdominal pain, enlarged abdomen, ovarian cysts, nausea, and upper respiratory infections.  Men using Gonal-f® have commonly reported acne, breast pain and growth, fatigue.  Injection site reactions have been reported. 

Please see prescribing information enclosed for full disclosure.